Drug Interactions: GHB

As we all know, some drugs cannot be taken together. We are pretty careful not to mix these, but what if your drink is spiked and you are taking a prescribed drug which may interact with the spike drug? You're best to find out what the interactions are, and see if your medications are on that list. Get yourself to an A&E if you suspect any sort of interaction, as you can't be sure what drug was used to spike your drink until a blood or urine test has been taken. Don't waste time wondering whether the drugs will interact, seek medical attention immediately.

GHB INTERACTIONS (GHB is also called Sodium Oxybate)
The combined use of alcohol with sodium oxybate (GHB) may result in potentiation of the central nervous system-depressant effects of sodium oxybate. Patients should be warned against the use of any alcoholic beverages in conjunction with sodium oxybate.
Sodium oxybate should not be used in combination with sedative hypnotics or other CNS depressants.
Drug interaction studies in healthy adults demonstrated no pharmacokinetic interactions between sodium oxybate and protriptyline hydrochloride (an antidepressant), zolpidem tartrate (a hypnotic), and modafinil (a stimulant). However, pharmacodynamic interactions with these drugs have not been assessed.
The co-administration of omeprazole (a drug that alters gastric pH) has no clinically significant effect on the pharmacokinetics of sodium oxybate. The dosage of sodium oxybate therefore does not require adjustment when given concomitantly with proton pump inhibitors.
Studies in vitro with pooled human liver microsomes indicate that sodium oxybate does not significantly inhibit the activities of the human isoenzymes.
Since sodium oxybate is metabolised by GHB dehydrogenase there is a potential risk of an interaction with drugs that stimulate or inhibit this enzyme (e.g. valproate, phenytoin or ethosuximide). No interaction studies have been conducted in human subjects
Sodium oxybate has been administered concomitantly with CNS stimulant agents in approximately 80 % of patients in clinical studies. Whether this affected respiration during the night is unknown.
Antidepressants have been used in the treatment of cataplexy. A possible additive effect of antidepressants and sodium oxybate cannot be excluded. The rate of adverse events have increased when sodium oxybate is co-administered with tricyclic antidepressants.